An observational study in Solid Tumor Malignancies, Hematologic Cancer and Lung Cancer, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Peking University First Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.
Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 10th largest by planned enrollment of the 24 observational ones that give a count, is one of 20 that started in 2026, is one of 24 observational ones, reaches primary completion later than 69 of the 82 other live ones, and was the 116th registered.
1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Ascentage Pharma Group Inc. · Sites in China, United States
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 41 · Phase 3 15 · Phase 4 5
First in 2008; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 186 across 322 observational studies indexed under Hematologic Neoplasms.
Median enrollment 56 across the 123 interventional studies, 88 across the 24 observational. Of the 32 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 148 have an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 392 studies on the registry; 187 are open to participants now.
Peking University First Hospital has 2 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Hematologic Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07014449Hangzhou Weben Pharma Co., LtdClinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | 2026-12 |
| NCT06066203Sichuan Baili Pharmaceutical Co., Ltd.A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
| NCT06225856Shanghai Yuyao Biotech Co., Ltd.An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | 2026-12-30 |
| NCT05255926Zhongnan HospitalCXCR4-targeted PET/CT Imaging in Hematological Malignancies | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 148 studies in Hematologic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
It is urgent to select patients who will benefit from immunotherapy, so as to help the clinicians adjust the regimens and avoid unnecessary side effect. 18F-G1 is a new radioactive tracer targeting granzyme B, holding great promise in assessing early response to immunotherapy. This study will explore the safety of 18F-G1 PET/CT in patients with solid tumors and hematological tumors receiving immunotherapy, analyze its imaging features, and assess its efficacy in predicting early immunotherapy response and prognosis, so as to aid the clinicians in precise patient stratification and regimen adjustment.
Subjects diagnosed with a malignant tumor (solid tumor or hematological tumor) by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
Number of participants with 18F-G1-related adverse events (AEs).
The absolute number of participants with AEs after the injection of 18F-G1 according to CTCAE 5.0.
Time frame: 3 days after the injection of 18F-G1
Tumor uptake of 18F-G1
The uptake of 18F-G1 in tumors will be quantitatively assessed by SUVmax.
Time frame: 40-60 minutes after the injection of 18F-G1
Liver uptake of 18F-G1
The uptake of 18F-G1 in liver will be quantitatively assessed by SUVmax.
Time frame: 40-60 minutes after the injection of 18F-G1
Lung uptake of 18F-G1
The uptake of 18F-G1 in lung will be quantitatively assessed by SUVmax.
Time frame: 40-60 minutes after the injection of 18F-G1
Kidney uptake of 18F-G1
The uptake of 18F-G1 in kidney will be quantitatively assessed by SUVmax.
Time frame: 40-60 minutes after the injection of 18F-G1
the granzyme B specificity of 18F-G1
Time frame: 3 years
Assessing the early predictive value of 18F-G1 PET/CT for immunotherapy response.
Participants' overall response will be assessed by RECIST 1.1 criteria or Lugano criteria at the time point of 6 months after immunotherapy. The tumor uptake of 18F-G1 will be compared between the responders and non-responders.
Time frame: 6 months
Evaluate the correlation of 18F-G1 accumulation in tumors to long term survival after immunotherapy.
Participants will be categorized into groups with high or low 18F-G1 uptake in tumor lesions. The progression-free survival (PFS) as assessed by RECIST 1.1 criteria or Lugano criteria will be compared between the two groups.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 322. This study's planned 26 months is below that.
Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: start Jul 2025 → Sep 2026, primary completion Dec 2026 → Dec 2028 and completion Jun 2027 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →